Literature DB >> 14550434

Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome.

Kent G Krejci1, Michael L Blute, John C Cheville, Thomas J Sebo, Christine M Lohse, Horst Zincke.   

Abstract

OBJECTIVES: To determine the clinicopathologic features associated with outcome in patients with sporadic renal cell carcinoma (RCC) treated with nephron-sparing surgery.
METHODS: We studied 344 patients treated with nephron-sparing surgery between 1970 and 2000. The pathologic features of the tumors were reviewed by two urologic pathologists who recorded the histologic subtype, 2003 TNM stage, tumor size, and grade. Cancer-specific survival (CSS) was estimated using the Kaplan-Meier method, and log-rank tests were used to compare the outcome by histologic subtype. Univariate Cox proportional hazards models were fit to assess the associations between the clinicopathologic features and death from RCC, distant metastases, and local recurrence.
RESULTS: The CSS rate at 5 and 10 years for patients with clear cell RCC was 94.4% and 91.5%, respectively. In contrast, the CSS rate at 5 and 10 years for patients with papillary or chromophobe RCC was 99.0%, because only 1 patient died of papillary RCC and no patient died of chromophobe RCC (P = 0.029). Among the patients with localized clear cell RCC, tumor stage and grade were significantly associated with death from RCC and metastases. Grade was significantly associated with local recurrence for clear cell RCC, but not for papillary RCC.
CONCLUSIONS: In our series of patients with RCC treated with nephron-sparing surgery, patients with clear cell RCC had a significantly worse CSS than did patients with papillary and chromophobe RCC. Tumor stage and grade were associated with outcome among patients with localized clear cell RCC. These findings are similar to the results for patients with localized clear cell RCC treated with radical nephrectomy.

Entities:  

Mesh:

Year:  2003        PMID: 14550434     DOI: 10.1016/s0090-4295(03)00489-8

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Gross intraoperative evaluation (GIE): a reliable method for the evaluation of surgical margins at partial nephrectomy.

Authors:  Hasan Yilmaz; Seyfettin Ciftci; Levend Ozkan; Ali Saribacak; Kursat Yildiz; Ozdal Dillioglugil
Journal:  Int J Clin Exp Med       Date:  2014-03-15

2.  Advances of multidetector computed tomography in the characterization and staging of renal cell carcinoma.

Authors:  Athina C Tsili; Maria I Argyropoulou
Journal:  World J Radiol       Date:  2015-06-28

Review 3.  Best Practice No 180. Nephrectomy for renal tumour; dissection guide and dataset.

Authors:  S Fleming; D F R Griffiths
Journal:  J Clin Pathol       Date:  2005-01       Impact factor: 3.411

Review 4.  [Recurrent disease in renal cell carcinoma. "Local recurrence" after kidney-sparing and radical resection].

Authors:  M Löhr; D Rohde
Journal:  Urologe A       Date:  2005-04       Impact factor: 0.639

5.  The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery.

Authors:  Pierre Bigot; Jean-Christophe Bernhard; Inderbir S Gill; Nam Son Vuong; Grégory Verhoest; Vincent Flamand; Boris Reix; Evren Suer; Ilker Gökce; Jean Baptiste Beauval; François Xavier Nouhaud; Masatoshi Eto; Eduard Baco; Toru Matsugasumi; Yvonne Chowaniec; Jérôme Rigaud; Claire Lenormand; Christian Pfister; Jean François Hetet; Guillaume Ploussard; Morgan Roupret; Priscilla Léon; Adnan El Bakri; Stéphane Larré; Xavier Tillou; Arnaud Doerfler; Aurélien Descazeaud; Nicolas Koutlidis; Alexandre Schneider; Philippe Sebe; Alexandre Ingels; Abdel Rahmène Azzouzi; Michel Soulié; Arnaud Méjean; Karim Bensalah; Jean-Jacques Patard
Journal:  World J Urol       Date:  2015-07-07       Impact factor: 4.226

6.  The contemporary role of surgery in kidney cancer.

Authors:  J B Lattouf; Q D Trinh; F Saad
Journal:  Curr Oncol       Date:  2009-05       Impact factor: 3.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.